BG Medicine Stock (OTC:BGMD), Trade Ideas

BG Medicine Inc manufacture and sell diagnostic products that are used to guide the patients suffering from heart failure and related disorders in the United States. It distributes its products such as BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme-linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

AEMD

AGTK

AJXGF

AMHPF

APPZ

APWC

ARXRF

AXCG

BGMD

BKQNY

BRTX

CBAY

CBYI

CHDGF

CPMMF

CREG

CRUUF

CVTI

DAUGF

DIRV

DKAM

DLOC

DTNOF

ERBA

EUOT

FNLPF

FUGMF

GMHLF

GREEN 2 BLUE ENERGY CORP by Green 2 Blue Energy Corp.

GTGEF

HAIPF

HEAR

HHPHF

HPMM

HVBTF

IDXG

IJJP

IMBBY

ITRN

IVITF

JBFCY

KAEPY

KATFF

KOSS

KPOC

LJPC

LTNC

MACK

MGAWY

MMNFF

MRIN

NGPHF

NHTC

NRGMF

NTWK

NVIV

OCGN

PCYG

PDNLA

PRGX

PRPM

PSIX

PTMN

QCCO

RITE

ROSE

SDLPF

SIPC

SKVKY

SNOA

SPLP

SQNS

SADDLE RANCH MEDIA INC by Saddle Ranch Media, Inc.

SRMX

THTX

TOPS

TORSF

UBQU

ULTA

VISL

VISIUM TECHNOLOGIES INC by Visium Technologies, Inc.

VISM

VIVE

VICTORY SQUARE TECH ORD by Victory Square Technologies Inc

VSQTF

XREG

RSGUF

RGDFF

MIDLF

SQRMF

CZXMF

SKHRF

GDXRF

VANTF

Stocks That Hit 52-Week Lows On Monday

BZSUM

CAPN

EVEP

GALT

MXPT

OHGI

PLNR

TSLA

Mid-Day Market Update: Thursday&#39;s Movers, China, Tesla And More

CTRE

Stocks Hitting 52-Week Lows

BG Medicine Inc

BG Medicine Reports Withdrawl of 510(k) Premarket Notification for Proposed Added Indication for BGM Galectin-3 Test

Earnings

BG Medicines Reports Q2 Loss of $0.23/Share, Sales $505K

Thursday&rsquo;s market session was driven by the U.S. jobless claims report along with China&rsquo;s public defense of its handling of the yuan. The markets on Thursday were as follows: Dow Jones Industrial Average: Up 0.30 percent, S&amp;P 500: Down 0.25 percent, NASDAQ Composite: Up 0.44 percent, US Dollar Index: Up 0.19 percent, 10 Year Treasury: Up 0.040 percent and Crude Oil WTI: Down 2.47 percent.

	China&rsquo;s central bank on Thursday suggested in a rare public defense that the Yuan will stabilize, specifying that it sees no reason for a further decline and will ultimately regain its growth; Yi Gang, the People&rsquo;s Bank of China&rsquo;s Vice Governor stated that China contains the &ldquo;financial firepower&rdquo; to defend the currency as needed, according to the<a href="http://www.wsj.com/articles/chinas-yuan-opens-weaker-1439429932"> Wall Street Journal</a>. He concluded that &ldquo;a fixed exchange rate looks stable, but it hides accumulated problems.&rdquo;

	The number of Americans filing for unemployment benefits unexpectedly increased 5,000 last week to 274,000, up 4,000 from just the week before. The Labor Department continues to hint at a trend pointing to a strengthening labor market.

	Tesla Motors Inc (NASDAQ: <a class="ticker" href="/stock/tsla#NASDAQ">TSLA</a>) announced that it will sell its shares in order to raise $500 million, with Founder and CEO Elon Musk committing to purchasing nearly 84,000 shares, totaling to about $20 million. The company stated that it intended to use the money for the development of its energy business, its battery Gigafactory, Tesla&rsquo;s Model 3 project, and other general purposes.
<h3>
	Winners</h3>

	Capnia Inc (NASDAQ: <a class="ticker" href="/stock/capn#NASDAQ">CAPN</a>) skyrocketed a whopping 92 percent after the company reported a 16.8 percent drop in its short interest. An officer of Capnia, David D O&rsquo;Toole bought 10,000 shares of his company for $1.78 per share on Wednesday.

	Planar Systems Inc (NASDAQ: <a class="ticker" href="/stock/plnr#NASDAQ">PLNR</a>) soared 34 percent after the electronics manufacturer entered into a definitive agreement to be acquired by Leyard Optoelectronic for nearly $157 million.

	One Horizon Group Inc (NASDAQ: <a class="ticker" href="/stock/ohgi#NASDAQ">OHGI</a>) was lifted 33 percent after the communications company&rsquo;s Aishuo app won an exclusive supply contract for satellite operator KeyIdea.

	Galectin Therapeutics Inc (NASDAQ: <a class="ticker" href="/stock/galt#NASDAQ">GALT</a>) was up 15 percent after it received U.S. Patent Notice of allowance for use of Pectin compounds in order to reduce Fibrosis in multiple diseases.

	Wayfair Inc (NYSE: <a class="ticker" href="/stock/w#NYSE">W</a>) increased again at the rate of 15 percent after the company reported that its loss narrowed in Q2 and sales grew. This is the first time the company, since its IPO, has reported narrower losses in two consecutive quarters.
<h3>
	Losers</h3>

	BG Medicine Inc (NASDAQ: <a class="ticker" href="/stock/bgmd#NASDAQ">BGMD</a>) dwindled 38 percent after it priced its offering of 2,315,654 Series A units and 184,346 Series B units for $1.00 per unit.

	MaxPoint Interactive Inc (NYSE: <a class="ticker" href="/stock/mxpt#NYSE">MXPT</a>) declined 26 percent after the company reported sales of $34.5 million, a 36 percent year-over-year increase, but in the month of June, a change in customers actively led to a slowdown for the company. CEO Brad Schomber commented that the &ldquo;unusual change was the largest we have experienced.&rdquo;

	Comstock Resources Inc (NYSE: <a class="ticker" href="/stock/crk#NYSE">CRK</a>) was down 17 percent after the company released Q2 results.

	EV Energy Partners LP (NASDAQ: <a class="ticker" href="/stock/evep#NASDAQ">EVEP</a>) sank 16 percent after the company reported a loss of $7.85 million, or a loss of $0.26 per share on sales of $21.6 million.

	Copa Holdings SA (NYSE: <a class="ticker" href="/stock/cpa#NYSE">CPA</a>) was shot down 13 percent after the company announced a profit of $64.1 million, or $0.93 per share, versus analyst expectations of $1.10 per share.

Mid-Day Market Update: Thursday's Movers, China, Tesla And More

Copa Holdings, S.A. (NYSE: <a class="ticker" href="/stock/cpa#NYSE">CPA</a>) shares fell 12.38 percent to reach a new 52-week low of $64.07. Copa Holding reported Q2 adjusted earnings of $0.93 per share on revenue of $538.4 million. Credit Suisse downgraded Copa Holdings from Outperform to Neutral and lowered the price target from $130.00 to $80.00.
 Kronos Worldwide, Inc. (NYSE: <a class="ticker" href="/stock/kro#NYSE">KRO</a>) shares dropped 5.53 percent to touch a new 52-week low of $7.51. Kronos Worldwide shares have dropped 49.17 percent over the past 52 weeks, while the S&amp;P 500 index has surged 6.69 percent in the same period.
 BG Medicine, Inc. (NASDAQ: <a class="ticker" href="/stock/bgmd#NASDAQ">BGMD</a>) shares reached a new 52-week low of $0.915 after the company priced its 2,315,654 Series A unit offering at $1 per unit and 184,346 Series B units at $1 per share.
 Caretrust REIT Inc (NASDAQ: <a class="ticker" href="/stock/ctre#NASDAQ">CTRE</a>) shares touched a new 52-week low of $10.44 after the company priced offering of 14,200,000 shares at $10.50 per share.

BG Medicine, Inc. (NASDAQ: <a class="ticker" href="/stock/bgmd#NASDAQ">BGMD</a>) shares tumbled 40.53 percent to $0.880 after the company priced its 2,315,654 Series A unit offering at $1 per unit and 184,346 Series B units at $1 per share.
Rockwell Medical Inc (NASDAQ: <a class="ticker" href="/stock/rmti#NASDAQ">RMTI</a>) dropped 13.39 percent to $11.90. Morgan Stanley initiated coverage on Rockwell Medical with a Underweight rating and a $7.00 price target.
Sizmek Inc (NASDAQ: <a class="ticker" href="/stock/szmk#NASDAQ">SZMK</a>) shares fell 7.38 percent to $6.65. Sizmek reported a Q2 loss of $0.27 per share on revenue of $40.216 million.
 Shake Shack Inc (NYSE: <a class="ticker" href="/stock/shak#NYSE">SHAK</a>) shares declined 8.46 percent to $59.50 after the company priced its 4 million share secondary offering at $60 per share.
 Kohl's Corporation (NYSE: <a class="ticker" href="/stock/kss#NYSE">KSS</a>) shares dropped 8.18 percent to $56.47 after the company reported weaker-than-expected results for the second quarter.
 Caretrust REIT Inc (NASDAQ: <a class="ticker" href="/stock/ctre#NASDAQ">CTRE</a>) shares slipped 5.25 percent to $10.47 after the company priced offering of 14,200,000 shares at $10.50 per share.
 Randgold Resources Ltd. (ADR) (NASDAQ: <a class="ticker" href="/stock/gold#NASDAQ">GOLD</a>) shrank 3.60 percent to $62.90 after gaining 4.82 percent on Wednesday. Gold futures fell 0.80 percent to $1,114.60 an ounce.

GOLD

RMTI

SHAK

SZMK

Morning Market Losers

Offerings

BG Medicine Prices 2.315M Unit Offering At $1/Unit, Prices 184K Series B Units At $1/Share

BG Medicine Announces Proposed Offering of Stock

BG Medicine, Inc. (Nasdaq: <a class="ticker" href="/stock/bgmd#Nasdaq">BGMD</a>), the developer of the BGM Galectin-3® Test, today announced the effectiveness of a one-for-four reverse stock split of its common stock. The reverse stock split took effect at 5:00 pm Eastern Time on July 8, 2015 and the Company's common stock will open for trading on the NASDAQ Capital Market on July 9, 2015 on a post-split basis.
The reverse stock split is intended to increase the per share trading price of the Company's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market. As a result of the reverse stock split, every four shares of the Company's common stock issued and outstanding prior to the opening of trading on July 9, 2015 will be consolidated into one issued and outstanding share, except to the extent that the reverse stock split results in any of the Company's stockholders owning a fractional share, which would be rounded up to the next highest whole share. In connection with the reverse stock split, there will be no change in the nominal par value per share of $0.001.
Trading of the Company's common stock on the NASDAQ Capital Market will continue, on a split-adjusted basis, with the opening of the markets on Thursday, July 9, 2015, under the existing trading symbol "BGMD" but with a new CUSIP number 08861T206. The reverse stock split reduces the number of shares of the Company's common stock outstanding from approximately 34.6 million pre-reverse split shares to approximately 8.6 million post-reverse split shares.
The Company has retained its transfer agent, Computershare Trust Company, N.A. ("Computershare"), to act as its exchange agent for the reverse split. Computershare will provide stockholders of record as of the effective date a letter of transmittal providing instructions for the exchange of their certificates. Stockholders owning shares via a broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to brokers' particular processes, and will not be required to take any action in connection with the reverse stock split.
The reverse stock split was approved within a range of one-for-two to one-for-six by the Company's stockholders at the 2015 Annual Meeting of Stockholders held on July 7, 2015 and the specific ratio of one-for-four was subsequently approved by the Company's Board of Directors. For more information regarding the reverse stock split, please refer to the Company's definitive proxy statement filed with the Securities and Exchange Commission on Schedule 14A on June 9, 2015.

Stock Split

BG Medicine Announces One-for-Four Reverse Stock Split

BG Medicine, Inc. (Nasdaq: <a class="ticker" href="/stock/bgmd#Nasdaq">BGMD</a>), the developer of the BGM Galectin-3® Test, today announced that the ARCHITECT® Galectin-3 assay is now available. This automated blood test was cleared by the United States Food and Drug Administration (FDA) for use in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure. The ARCHITECT Galectin-3 assay is performed using the Abbott ARCHITECT automated immunoassay analyzer and is being commercialized through an agreement between BG Medicine and Abbott.
"We believe that the introduction of automated galectin-3 testing will improve access to galectin-3 testing, shorten turn-around time for delivery of test results, and, as a result, accelerate adoption of galectin-3 testing in the United States," said Paul R. Sohmer, M.D., President and CEO of BG Medicine, Inc.

Press Releases

First Automated Test for Galectin-3 Now Available in U.S.

BG Medicine Files $75 Mixed Shelf Accordign to S-3

BG Medicine Q1 EPS -$0.04 vs -$0.03 est, Revenue 0.44M vs 1.6M est

BG Medicine Issues Submission of 510(k) to FDA Related to Added Indication for BGM Galectin-3(R)

Conns Inc. (NASDAQ: <a class="ticker" href="/stock/conn#NASDAQ">CONN</a>) is expected to report its Q4 earnings at $0.63 per share on revenue of $420.73 million.
Movado Group, Inc. (NYSE: <a class="ticker" href="/stock/mov#NYSE">MOV</a>) is projected to report its Q4 earnings at $0.20 per share on revenue of $134.31 million.
Science Applications International Corporation (NYSE: <a class="ticker" href="/stock/saic#NYSE">SAIC</a>) is estimated to report its Q4 earnings at $0.71 per share on revenue of $935.70 million.
SORL Auto Parts, Inc. (NASDAQ: <a class="ticker" href="/stock/sorl#NASDAQ">SORL</a>) is projected to report its Q4 earnings at $0.12 per share on revenue of $55.91 million.
SYNNEX Corp. (NYSE: <a class="ticker" href="/stock/snx#NYSE">SNX</a>) is estimated to post its Q1 earnings at $1.52 per share on revenue of $3.42 billion.
Vertex Energy, Inc. (NASDAQ: <a class="ticker" href="/stock/vtnr#NASDAQ">VTNR</a>) is estimated to report a Q4 loss at $0.09 per share on revenue of $76.66 million.
Ducommun Inc. (NYSE: <a class="ticker" href="/stock/dco#NYSE">DCO</a>) is expected to post its Q4 earnings at $0.30 per share on revenue of $184.55 million.
Vitae Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="/stock/vtae#NASDAQ">VTAE</a>) is projected to report a Q4 loss at $0.40 per share on revenue of $100.00 thousand.
Acorn Energy, Inc. (NASDAQ: <a class="ticker" href="/stock/acfn#NASDAQ">ACFN</a>) is estimated to post a Q4 loss at $0.13 per share on revenue of $7.10 million.
 Real Goods Solar, Inc. (NASDAQ: <a class="ticker" href="/stock/rgse#NASDAQ">RGSE</a>) is expected to post a Q4 loss at $0.20 per share on revenue of $23.90 million.
Paragon Shipping Inc. (NASDAQ: <a class="ticker" href="/stock/prgn#NASDAQ">PRGN</a>) is projected to post a Q4 loss at $0.22 per share on revenue of $12.66 million.
Landec Corp. (NASDAQ: <a class="ticker" href="/stock/lndc#NASDAQ">LNDC</a>) is expected to post its Q3 earnings at $0.14 per share on revenue of $135.73 million.
NovaGold Resources Inc. (NYSE: <a class="ticker" href="/stock/ng#NYSE">NG</a>) is estimated to post a Q1 loss at $0.02 per share.
Flexible Solutions International Inc. (NYSE: <a class="ticker" href="/stock/fsi#NYSE">FSI</a>) is projected to post its Q4 earnings at $0.02 per share on revenue of $3.96 million.
Freshpet, Inc. (NASDAQ: <a class="ticker" href="/stock/frpt#NASDAQ">FRPT</a>) is estimated to post a Q4 loss at $0.02 per share on revenue of $23.88 million.
Perma-Fix Environmental Services Inc. (NASDAQ: <a class="ticker" href="/stock/pesi#NASDAQ">PESI</a>) is expected to report its Q4 earnings at $0.16 per share on revenue of $17.21 million.
BG Medicine, Inc. (NASDAQ: <a class="ticker" href="/stock/bgmd#NASDAQ">BGMD</a>) is estimated to report a Q4 loss at $0.05 per share on revenue of $800.00 thousand.
Hooper Holmes Inc. (NYSE: <a class="ticker" href="/stock/hh#NYSE">HH</a>) is projected to report its Q4 earnings.

Pre-Market Outlook

ACFN

CONN

FRPT

LNDC

PESI

PRGN

RGSE

SAIC

SORL

VTAE

VTNR

Earnings Scheduled For March 31, 2015

BG Medicine (Nasdaq: <a class="ticker" href="/stock/bgmd#Nasdaq">BGMD</a>) announced today the publication of a landmark study, in the Journal of the American College of Cardiology, reporting clinical outcome results of the BioImage Study.[1] The BioImage Study, sponsored by BG Medicine in collaboration with pharmaceutical and healthcare companies Abbott, AbbVie, AstraZeneca, Merck, Philips, and Takeda, is a large, prospective study of cardiovascular disease in asymptomatic men and women in the United States. The BioImage Study recruited 7,687 men and women above the age of 55 and monitored them for approximately 3 years for the occurrence of major cardiovascular events such as heart attack, stroke, and death due to cardiovascular causes.
	The recent publication appeared in the March 24, 2015 issue of the Journal of the American College of Cardiology, the flagship journal of the American College of Cardiology. The lead authors, from the Mount Sinai Medical Center in New York, reported the occurrence of 216 first major adverse cardiovascular events in BioImage Study participants during the follow-up period. Of these, the authors found that 184 events, or over 85% of all events, occurred in individuals who were believed at the outset of the study to be at
 <a href="http://www.benzinga.com/pressreleases/15/03/g5358699/bg-medicine-welcomes-major-publication-on-the-bioimage-study-in-the-jou">See full press release</a>

BG Medicine Welcomes Major Publication on BioImage Study in  Journal of the American College of Cardiology

BG Medicine (Nasdaq: <a class="ticker" href="/stock/bgmd#Nasdaq">BGMD</a>) announced today its receipt of a favorable decision from the Listing Qualifications Department (the "Staff") of The NASDAQ Stock Market LLC ("NASDAQ"), which granted the Company's request for continued listing on NASDAQ, pursuant to an extension within which to evidence compliance with NASDAQ Listing Rule 5550(b) (the "Rule"). In the Company's case, the Rule requires the Company to evidence either a minimum of $2.5 million in stockholders' equity or a market capitalization of at least $35 million. The Company is diligently working to evidence compliance with the Rule on or before May 19, 2015, as required by the Staff.
 <a href="http://www.benzinga.com/pressreleases/15/02/g5199392/bg-medicine-announces-receipt-of-favorable-nasdaq-listing-determination">See full press release</a>

BG Medicine Receives Favorable NASDAQ Listing Determination

BG Medicine Announces FDA Made Publicly Available the 510(k) Clearance for Premarket Notification Number K140436, The First Automated Version of Galectin-3 Testing to Receive Regulatory Clearance in US -8-K

Ladenburg Thalmann downgrades BG Medicine, Inc. (NASDAQ: <a class="ticker" href="/stock/bgmd#NASDAQ">BGMD</a>) from Buy to Neutral, according to Bloomberg.

Downgrades

Analyst Ratings

Ladenburg Thalmann Downgrades BG Medicine, Inc. to Neutral

BG Medicine, Inc. (NASDAQ: <a class="ticker" href="/stock/bgmd#NASDAQ">BGMD</a>) reports Q3 EPS of $(0.07) versus the estimated $(0.07), inline. EPS were Up 46% from the same quarter last year. Revenue came in at $695.0K versus the estimated $800.0K. Sales were Down 33% year over year.

BG Medicine, Inc. Reports Q3 EPS of $(0.07), Inline; Revenue of $695.0K vs $800.0K Est

Guidance

8-K from BG Medicine Shows Co. Implemented (on Sept. 11th) Reduction of ~55% of Workforce (12 Employees); Sees ~$300K One-Time Related Charge

BG Medicine

BG Medicine, Inc.

-

-

-

-

-

-

-

25% Off Benzinga's Most Powerful Trading Tools

-

-

-

-

-

-

-

BG Medicine Stock (OTC:BGMD), Trade Ideas